Peptides DB
Research-centric peptide and protocol reference hub
Study 9 of 21Setmelanotide literaturebiorxiv-preprint · Observational2023

Human HYPOMAP: A comprehensive spatio-cellular map of the human hypothalamus

This study offers a detailed transcriptional map of the human hypothalamus, identifying neuronal populations linked to BMI, but clinical applications are not yet established.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the setmelanotide corpus
3
Preclinical
12
Observational · this one
0
Open-label
2
Randomised
4
Reviews

Summary and findings

This study presents a comprehensive spatio-cellular transcriptional map of the human hypothalamus, utilizing a single-nucleus sequencing database of 433,369 human hypothalamic cells. The research identifies distinct populations of arcuate nucleus POMC and AGRP neurons, as well as their receptors, and maps incretin receptor-expressing cells. The study finds that 182 neuronal clusters are significantly enriched in expression of BMI GWAS genes, driven by 375 effector genes.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
182 neuronal clusters significantly enriched in expression of BMI GWAS genes.2023

Abstract

The authors’ words, as biorxiv-preprint supplied them

The hypothalamus is a brain region that plays a key role in coordinating fundamental biological functions. However, our understanding of the underlying cellular components and circuitry, have, until recently, emerged primarily from rodent studies. Here, we combine a single-nucleus sequencing database of 433,369 human hypothalamic cells, with spatial transcriptomics, to present a comprehensive spatio-cellular transcriptional map of the human hypothalamus, the ‘HYPOMAP’. Analysing hypothalamic leptin melanocortin pathway neuronal populations that play a role in appetite control, we identify spatially distinct populations of arcuate nucleus POMC and AGRP neurons, and their receptors MC3R and MC4R . Next, we map the cells expressing incretin receptors, targets of the new generation of anti-obesity medications, and uncover transcriptionally distinct GLP1R and GIPR -expressing cellular populations. Finally, out of the 458 hypothalamic cell types in HYPOMAP, we find 182 neuronal clusters are significantly enriched in expression of BMI GWAS genes. This enrichment is driven by 375 ‘effector’ genes, with rare deleterious variants in 6 of these; MC4R , PCSK1 , POMC , CALCR , BSN and CORO1A , the last of which has previously not been linked to obesity; being significantly associated with changes in BMI at the population level. Thus, the HYPOMAP provides a detailed atlas of the human hypothalamus in a spatial context, and serves as an important resource to identify novel druggable targets for treating a wide range of conditions, including reproductive, circadian, and metabolic disorders.

Elsewhere in the Setmelanotide corpus

DSetmelanotide for the Treatment of Acquired Hypothalamic Obesity. Reply.The New England journal of medicine · 2026—AImpact of setmelanotide on metabolic syndrome risk in patients with proopiomelanocortin or leptin receptor deficiencies.The Journal of clinical endocrinology and metabolism · 2026 · Overall mean (SD) change in MetS-Z-BMI score after ∼1 year of treatment was -1.05 (0.88).HumanDObesity in Children Aged 2 to 12 Years: A Review.JAMA · 2026 · Intensive health behavior and lifestyle treatment reduces BMI by 0.7 compared with children who do not participate in intensive health behavior and lifestyle treatment.reviewAMeasuring Hunger Severity in Rare MC4R Pathway Diseases: Development and Psychometric Evaluation of the Most Hunger Item.Advances in therapy · 2023 · MWPC thresholds for Most Hunger were estimated as 1.5-2.6, 0.95-1.6, and 2.4-3.7, respectively.HumanBPositioning Incretin-Based and Next-Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta-Analyses.Diabetes, obesity & metabolism · 2026 · Not reported in abstract.reviewBEffectiveness and Safety of Setmelanotide in a Patient With a Heterozygous PCSK1 Deficiency.Obesity (Silver Spring, Md.) · 2026 · n=1 · 11.8% total weight loss over 3 monthsHuman